Yongman Kim, PhD

Chief Innovation Officer, Director, R&D

Dr. Kim has over 14 years of experience in the industry of cellular therapeutics. Prior to working for NKMAX, he served as the GMP and R&D Center Director for Pharmicell Co., Ltd, a well-known Korean Stem Cell Biopharmaceutical Company, where he successfully obtained the first stem cell therapy KFDA approval in Korea. Prior to working in the Industry, Dr. Kim was a research Professor at Wonkwang University School of Medicine. He has been a visiting Fellow for the Genetic Pharmacology Unit in NINDS, the Neurobiological branch of the National Institute of Health. He had his Post-Doc. at the Department of Immunology at the Korea Research Institute of Bioscience and Biotechnology. He earned his PhD in Cell Biology from Chungnam National University in Korea.